Limits...
Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy.

Daram M, Montazeri G, Karimzadeh H, Malekzadeh R, Mahmoodi M, Goodarzi Z, Keyvani H, Mirmomen S, Alavian SM, Roggendorf M, Jazayeri SM - Iran J Basic Med Sci (2014)

Bottom Line: In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively. 32 (42%) of 76 amino acid changes occurred within immune epitopes.There were no differences in age, gender, and duration of chronicity in both patient and control groups in terms of the frequency and the patterns of mutations.Newer strategies should be considered based on third generation or the use of DNA vaccines or new adjuvants.

View Article: PubMed Central - PubMed

Affiliation: Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT

Objective s: The aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients.

Materials and methods: 16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples prior to vaccination and six months after the third dose.

Results: Only one patient lost HBsAg. 48 and 44 amino acid mutations were found before and after vaccine therapy in the vaccine group respectively, 51 of which (55.4%) occurred in immune epitopes: 5 were in B cell, 21 in T helper (Th), and 25 in cytotoxic T-lymphocyte (CTL) epitopes. In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively. 32 (42%) of 76 amino acid changes occurred within immune epitopes. There were no differences in age, gender, and duration of chronicity in both patient and control groups in terms of the frequency and the patterns of mutations.

Conclusion: In chronic carriers who already had HBsAg variants selected by the host-immune response, any immune stimulation by the vaccine had no effect on the chronic state of these patients or selected any remarkable escape mutants. Newer strategies should be considered based on third generation or the use of DNA vaccines or new adjuvants.

No MeSH data available.


Related in: MedlinePlus

Diagram shows percentage of mutations frequency in recipient vaccine and control group at the same time
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4322145&req=5

Figure 1: Diagram shows percentage of mutations frequency in recipient vaccine and control group at the same time

Mentions: All HBV patients were assigned to genotype D, subtype ayw2 (results not shown). One out of sixteen patients was responsive to vaccine, i. e. became HBV DNA and HBsAg negative . Overall, at the nucleotide level, 310 and 272 point mutations (before and after vaccine therapy) were found in the patient and the control group, respectively (Figure 1). 92 (29.6%) and 218 (70.3%) of those changes seen in the patient group were missense and silent substitutions, respectively (results are not shown). In the control group, 76 (24.3%) and 195 (75.7%) of nucleotide changes were missense and silent mutations, respectively (results are not shown). The nucleotide mutation frequencies in the patient and control groups were 2.3 and 2.5, respectively. 28 and 44 amino acid mutations were found before and after vaccine therapy in the patient group (Figure 1). In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively (Figure 1). A summary of amino acid changes within the surface proteins is shown in Tables 1 and 2.


Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy.

Daram M, Montazeri G, Karimzadeh H, Malekzadeh R, Mahmoodi M, Goodarzi Z, Keyvani H, Mirmomen S, Alavian SM, Roggendorf M, Jazayeri SM - Iran J Basic Med Sci (2014)

Diagram shows percentage of mutations frequency in recipient vaccine and control group at the same time
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4322145&req=5

Figure 1: Diagram shows percentage of mutations frequency in recipient vaccine and control group at the same time
Mentions: All HBV patients were assigned to genotype D, subtype ayw2 (results not shown). One out of sixteen patients was responsive to vaccine, i. e. became HBV DNA and HBsAg negative . Overall, at the nucleotide level, 310 and 272 point mutations (before and after vaccine therapy) were found in the patient and the control group, respectively (Figure 1). 92 (29.6%) and 218 (70.3%) of those changes seen in the patient group were missense and silent substitutions, respectively (results are not shown). In the control group, 76 (24.3%) and 195 (75.7%) of nucleotide changes were missense and silent mutations, respectively (results are not shown). The nucleotide mutation frequencies in the patient and control groups were 2.3 and 2.5, respectively. 28 and 44 amino acid mutations were found before and after vaccine therapy in the patient group (Figure 1). In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively (Figure 1). A summary of amino acid changes within the surface proteins is shown in Tables 1 and 2.

Bottom Line: In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively. 32 (42%) of 76 amino acid changes occurred within immune epitopes.There were no differences in age, gender, and duration of chronicity in both patient and control groups in terms of the frequency and the patterns of mutations.Newer strategies should be considered based on third generation or the use of DNA vaccines or new adjuvants.

View Article: PubMed Central - PubMed

Affiliation: Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT

Objective s: The aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients.

Materials and methods: 16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples prior to vaccination and six months after the third dose.

Results: Only one patient lost HBsAg. 48 and 44 amino acid mutations were found before and after vaccine therapy in the vaccine group respectively, 51 of which (55.4%) occurred in immune epitopes: 5 were in B cell, 21 in T helper (Th), and 25 in cytotoxic T-lymphocyte (CTL) epitopes. In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively. 32 (42%) of 76 amino acid changes occurred within immune epitopes. There were no differences in age, gender, and duration of chronicity in both patient and control groups in terms of the frequency and the patterns of mutations.

Conclusion: In chronic carriers who already had HBsAg variants selected by the host-immune response, any immune stimulation by the vaccine had no effect on the chronic state of these patients or selected any remarkable escape mutants. Newer strategies should be considered based on third generation or the use of DNA vaccines or new adjuvants.

No MeSH data available.


Related in: MedlinePlus